Quartz 4

OFP LOs

18 min read

L27: Defining Orofacial Pain

  • Define and classify orofacial pain according to the 2020 IASP definition, distinguishing nociceptive, neuropathic, and nociplastic mechanisms, and explain how pain differs from nociception. High-yield: 2020 IASP definition revision, distinction between nociception and pain perception, three pain types with clinical examples, the mind-body connection. Lower: historical pain definitions, philosophical framing of pain experience.

  • Distinguish physiological (acute, protective) from pathophysiological (chronic, non-protective) pain presentations, and explain how the biopsychosocial model accounts for biological, psychological, and social factors in pain perception. High-yield: acute vs chronic pain paradigm shift, psychosocial dominance in chronic pain, biopsychosocial axes (I and II), clinical relevance to patient assessment. Lower: detailed neurobiological pathways, role of neuroplasticity.

  • Describe the sensory-discriminative and motivational-affective components of the pain experience, including how emotional, psychological, and contextual factors influence individual pain perception. High-yield: emotional and affective response to pain, patient subjectivity and catastrophizing, empathy-centered clinical approach, influence of prior experience and expectations. Lower: detailed brain anatomical circuits.

  • Explain the enhanced neurobiological basis for facial pain, including heightened amygdala activation and craniofacial nociceptive processing, and apply this to understanding the heightened psychological burden of orofacial pain. High-yield: why facial pain has greater emotional weight than pain elsewhere, lateral parabrachial nucleus activation, lack of habituation to facial stimuli. Lower: detailed receptor types and neurotransmitter cascades.

  • Define temporomandibular disorders (TMD) as musculoskeletal and neuromuscular conditions of the TMJs and masticatory muscles, and apply the diagnostic axes framework (Axis I: physical, Axis II: psychological) to classify orofacial pain conditions. High-yield: DC/TMD diagnostic criteria, Axis I and Axis II co-diagnosis, prevalence of TMD and orofacial pain, biopsychosocial diagnostic approach. Lower: individual TMD subtypes and management.

L28: History and Examination including DC/TMD

  • Perform a comprehensive orofacial pain history using structured pain-characterization prompts, including temporal behavior, pain quality, functional modification, and parafunctional triggers. High-yield: OPQRST framework, onset triggers, pain modifiers with jaw function, clenching/grinding habits, jaw locking/catching, TMJ noises. Lower: exotic congenital or systemic comorbidity screening.

  • Explain temporomandibular joint anatomy, including the disc, compartments, retrodiscal tissue innervation, and the concept of inherent joint instability, and relate these to clinical findings. High-yield: condyle-fossa incongruency, disc position and vascularity, retrodiscal tissue innervation, joint capsule loose arrangement. Lower: detailed vascular anatomy, accessory ligament function.

  • Understand the contemporary biopsychosocial model and multifactorial risk factors for temporomandibular disorder onset and chronicity, including genetic, environmental, and psychological contributions. High-yield: genetic predisposition, physical trauma, psychological distress, sensory processing dysfunction, pain amplification states. Lower: specific gene polymorphisms (COMT, MAO, BDNF), detailed neuroendocrine pathways.

  • Apply the Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) framework to diagnose pain-related disorders (myalgia, arthralgia, headache attributed to TMD) and joint disorders (disc displacements, degenerative joint disease, subluxation). High-yield: Axis I physical diagnoses using history (SQ) and examination (E) criteria, pain provocation testing, familiar pain reproduction, click vs crepitus distinction. Lower: Expanded Taxonomy for rare conditions, intramuscular electromyography monitoring.

  • Perform a systematic clinical examination using the DC/TMD protocol including palpation of masticatory muscles and TMJ with correct force thresholds, jaw movement assessment, and detection of TMJ noises and locking. High-yield: palpation force (0.5 kg lateral pole, 1.0 kg muscles), pain/familiar pain/referred pain distinction, opening patterns (deviation vs deflection), click identification. Lower: supplemental muscle areas, precise millimetre measurements.

  • Administer and interpret Axis II psychosocial screening tools (pain drawing, Graded Chronic Pain Scale, PHQ-4) to assess psychological distress and pain-related disability, informing prognosis and management planning. High-yield: PHQ-4 anxiety/depression screening, pain manikin for diffuse vs localised pain, disability impact assessment. Lower: detailed GCPS scoring intervals, alternative psychological assessment batteries.

  • Recognise the limitations of clinical examination for disc displacement diagnosis and understand when advanced imaging (MRI, CT/CBCT) is indicated versus the utility of the brief DC/TMD (bDC/TMD) protocol for general practice. High-yield: bDC/TMD efficiency for common cases in under 10 minutes, low specificity of clinical examination for disc position, imaging as adjunct only when findings will alter care. Lower: imaging modality selection criteria, Helkimo Index as outdated standard.

L29: Intracapsular Disorders of TMD

  • Understand TMJ anatomy, biomechanics, and the role of disc morphology and retrodiscal tissues in maintaining normal joint function and preventing pathology. High-yield: biconcave disc shape, disc-condyle coordination, bilaminar zone innervation and vascularisation. Lower: specific ligamentous attachments, squamotympanic fissure detail.

  • Differentiate the four DC/TMD disc displacement categories (with reduction, with reduction and intermittent locking, without reduction with limited opening, without reduction without limited opening) by clinical signs and imaging findings, including mechanisms of clicking and locking. High-yield: disc displacement with vs without reduction, clicking mechanics, closed-lock concept, MRI confirmation. Lower: Wilkes staging history, detailed disc position nomenclature.

  • Describe subluxation (patient self-reduction) and luxation (emergency open lock) as condylar hypermobility disorders distinct from disc displacement, including clinical presentation, causes (ligamentous laxity), and emergency management (syringe method, manual reduction). High-yield: subluxation self-reducibility, luxation as medical emergency, syringe and manual reduction techniques. Lower: post-reduction activity restrictions.

  • Explain the pathophysiology of intracapsular pain including arthralgia and arthritis, focusing on retrodiscitis and synovitis as inflammatory drivers and the distinction between soft and hard end-feel on examination. High-yield: retrodiscal tissue as pain source, synovitis and capsulitis, soft/hard end-feel differential. Lower: specific nociceptor subtypes.

  • Discuss degenerative joint disease (osteoarthrosis and osteoarthritis) including crepitus, radiographic findings (sclerosis, erosion, osteophytes, “bird’s-beak” appearance), and the pathophysiology of chronic mechanical overload. High-yield: crepitus as cardinal sign, CT/OPG findings, osteophyte morphology. Lower: chondromalacia progression detail.

  • Apply conservative management principles (education, soft diet, physical therapy, oral appliances, pharmacotherapy) and identify specialist-referral indications (persistent symptoms, recurrent locking, functional limitation), including arthrocentesis and arthroscopy. High-yield: conservative first-line approach, NSAIDs and muscle relaxants, splint offloading, specialist triggers. Lower: specific Botox dosing, individual SSRI choices.

  • Recognise prognostic factors influencing TMD outcomes including compliance, severity, chronicity, psychosocial factors, genetic predisposition, and presence of widespread chronic pain. High-yield: biopsychosocial influence on prognosis. Lower: specific genetic markers.

L30: Botulinum Toxin for Orofacial Pain

  • Explain the mechanism of action of botulinum toxin at the neuromuscular junction through SNARE protein cleavage and acetylcholine blockade, and how it inhibits pain-mediating neurotransmitters in sensory nerves. High-yield: SNARE protein cleavage (types A/C/E vs B/D/F/G), acetylcholine release blockade, analgesic mechanisms via Substance P/CGRP/glutamate inhibition. Lower: serotype variations, immunogenicity.

  • Discuss indications for botulinum toxin in orofacial pain management including trigeminal neuralgia, temporomandibular disorders, neuropathic pain, and chronic migraine prophylaxis, with evidence-based efficacy levels for each. High-yield: trigeminal neuralgia (83–91% pain improvement), muscular TMD (60–100 U bilateral dosing), chronic migraine PREEMPT protocol (155–195 U). Lower: burning mouth syndrome, persistent idiopathic dentoalveolar pain.

  • Describe contraindications, adverse effects, and complications of botulinum toxin including hypersensitivity, infection at injection sites, generalised neuromuscular disorders, pregnancy/breastfeeding, transient dysphagia, and long-term mandibular bone-loss risk. High-yield: absolute contraindications (myasthenia gravis, infection, pregnancy), transient functional complications (dysphagia, nasal speech), immunogenicity/antibody formation. Lower: theoretical prion transmission via albumin, treatment failure causes.

  • Explain the available botulinum toxin preparations (Botox/Dysport/Xeomin/Myobloc) including their formulations, potency units, conversion ratios, and clinical differences in spread, onset, and storage. High-yield: Botox/Dysport (NAPs present), Xeomin (pure neurotoxin), non-bioequivalent dosing conversions (ONA:INCO 1:1, ONA:ABO 1:2.5). Lower: serotypes under clinical trials (BoNT/E, /F), manufacturing-specific testing methods.

  • Describe practical injection protocols for specific orofacial pain conditions including injection sites (masseter, temporalis, lateral/medial pterygoid, sphenopalatine ganglion), dosing ranges, localisation techniques (palpation, EMG, ultrasound), and needle gauges. High-yield: masseter/temporalis injection sites for TMD and dystonia, lateral pterygoid for TMJ dislocation and refractory TMD, trigger-zone injections for trigeminal neuralgia. Lower: 30-gauge needle standard, colour Doppler for vascular safety, CAD-CAM guides for V2 access.

  • Discuss the evidence quality and limitations of botulinum toxin efficacy in different orofacial pain presentations, with strong evidence for chronic migraine and trigeminal neuralgia versus moderate-to-equivocal evidence for bruxism and myofascial TMD. High-yield: sufficient evidence for trigeminal neuralgia and masseter hypertrophy; equivocal/inconclusive for bruxism, TMJ articular disorders, myofascial pain. Lower: cost-benefit analysis gaps, heterogeneous study protocols, long-term dosing intervals.

L31: Occlusal Splint Therapy

  • Outline the rationale for splint therapy in TMD and bruxism, including proposed mechanisms (foreign-body reflex muscle relaxation, altered condylar loading, cognitive awareness), recognising that success is largely driven by regression to the mean and placebo effect. High-yield: mechanisms are theories only — not confirmed; placebo enhanced by clinician reputation and environment. Lower: eight competing theoretical explanations.

  • Compare major stabilisation splint designs (flat plane, Michigan, Tanner) versus anterior repositioning appliances for different TMD presentations: stabilisation for muscle disorders (first-line); anterior repositioning for disc displacement with acute pain or locking (careful patient selection). High-yield: hard stabilisation splints as first-line with strongest evidence; anterior repositioning reserved for Wilkes II with refractory symptoms due to risk of permanent occlusal/skeletal change. Lower: canine guidance vs flat plane — no evidence of superiority.

  • Distinguish NTI-tss and mini-anterior versus full-coverage stabilisation splints by efficacy and adverse effects: NTI-tss shows no difference or inferior efficacy for TMD symptoms with significant risk of anterior open bite and lower-anterior tooth mobility; stabilisation splints are more effective for pain reduction. High-yield: NTI-tss limitations and adverse effects; stabilisation splints as preferred design. Lower: AMPS vs stabilisation (no difference for myogenous pain), Lucia Jig mechanics.

  • Evaluate critically the evidence supporting occlusal splint efficacy: 2025 meta-analysis shows splints are not superior to other conservative treatments for pain and mouth opening but are more effective than counselling alone or placebo; stabilisation splints effective for arthralgia and TMD-attributed headache. High-yield: occlusal splints do not unload the TMJ (biomechanical myth), do not stop sleep bruxism itself, do not permanently recapture discs, and do not establish ideal occlusion. Lower: vertical dimension of occlusion changes as myth.

  • Explain why hard splints are preferred over soft splints — soft splints associated with increased EMG activity (“chewing-gum effect”) and short-term increase in sleep bruxism; hard splints are easier to adjust and supported by most studies. High-yield: hard over soft for TMD and bruxism management. Lower: material hardness spectrum (PMMA, PEEK, nylon, silicone) and flexural strength properties.

  • Describe the evidence against neuromuscular and fringe appliance designs: neuromuscular splints and myocentric positioning lack normative data, fail to enhance athletic performance, and lack scientific basis; pivot/fulcrum and hydrostatic (Aqualizer) splints similarly unsupported; posterior bite plane (MORA) shows no effect on muscular strength or athletic performance. High-yield: neuromuscular dentistry and athletic-performance claims are unsubstantiated. Lower: diagnostic systems (K7x, OccluSense, Noromed MES 9000) incapable of accurate jaw-movement recreation.

  • Recommend clinical appliance selection stratified by diagnosis: muscle disorders → flat plane initially, advancing to anterior bite plane if refractory myofascial pain; disc displacements → flat plane, progressing to anterior repositioning for Wilkes II with locking; joint inflammation follows the same initial-to-advanced strategy; return to flat-plane stabilisation after symptom resolution. High-yield: diagnostic-based selection algorithm (Greene & Menchel 2018). Lower: progression criteria and timing for appliance changes.

L32: Non-Odontogenic Toothache

  • Describe the prevalence, aetiology, pathophysiology, clinical features, diagnosis, and management of the various conditions that may present as non-odontogenic toothache. High-yield: myofascial pain with trigger-point referral patterns, neurovascular pain (migraine, trigeminal autonomic cephalalgias), sinus-origin pain, cardiac referral pain, trigeminal neuralgia, neuropathic pain. Lower: somatic symptom disorder, post-traumatic trigeminal neuropathic pain.

  • Differentiate odontogenic from non-odontogenic toothache using history, clinical examination (pulp testing, response to percussion), diagnostic tests, and the critical distinction between site and source of pain. High-yield: referred pain vs primary pain, rationale for treating source not site, prevention of unnecessary endodontic treatment. Lower: specific diagnostic imaging modalities.

  • Explain the mechanism of referred pain in myofascial pain, including trigger-point activation, convergence theory at the trigeminal sensory complex, and anatomical referral patterns of masticatory and cervical muscles to dental regions. High-yield: anterior and posterior temporalis, masseter, and sternocleidomastoid referral patterns; antidromic transmission. Lower: detailed neurophysiology of convergence.

  • Discuss management strategies for non-odontogenic toothache, including conservative behavioural interventions, pharmacotherapy, physical therapy, trigger-point injections, occlusal splints for bruxism, and psychosocial referral where indicated. High-yield: patient education and reassurance, spray-and-stretch, habit reversal, local anaesthetic injection technique. Lower: botulinum toxin, surgical microvascular decompression.

  • Explain the clinical presentation and diagnostic approach to neurovascular pain (migraine and trigeminal autonomic cephalalgias) presenting as orofacial pain, including autonomic features such as tearing, congestion, and dental hypersensitivity. High-yield: demographics, pain characteristics, associated autonomic symptoms, allodynia. Lower: detailed migraine classification.

  • Discuss the diagnosis and management of sinus-origin toothache, including constant dull pain in maxillary posterior teeth, percussion sensitivity, and the role of imaging in ruling out sinusitis in virgin teeth. High-yield: viral vs bacterial aetiology, decongestants and nasal treatments, antibiotic indications. Lower: imaging protocols.

  • Explain cardiac-origin orofacial pain as a rare but life-threatening referral pattern caused by myocardial ischaemia, including substernal symptoms, associated dyspnoea and nausea, and the critical need for emergency management with aspirin. High-yield: convergence of vagus and trigeminal nerves, recognition of cardiac symptoms, emergency response. Lower: detailed cardiac physiology.

L33: Extracapsular Disorders of TMD

  • Discuss the aetiology, pathophysiology, clinical features, diagnosis, and conservative management of myalgia, including local myalgia, myofascial pain, and myofascial pain with referral. High-yield: palpation-based DC/TMD classification, trigger-point theory and central sensitisation mechanisms, nociceptor activation, self-care and physiotherapy as first-line. Lower: advanced pharmacotherapy and specialised injection protocols.

  • Describe the clinical presentation, diagnosis, and management of myositis and myositis ossificans (progressive and traumatic forms) affecting masticatory muscles. High-yield: acute pain and swelling on examination, CT imaging confirmation, surgical excision for traumatic form. Lower: progressive myositis ossificans (Münchmeyer’s disease) genetic and irreversible aspects.

  • Discuss the clinical features, aetiology, and acute management of myospasm and muscle cramps, including jaw-closing and jaw-opening types and their distinction by electromyography. High-yield: acute involuntary contraction with severely limited range of motion, ice and local-anaesthetic injection, muscle stretching. Lower: needle EMG diagnostic protocols.

  • Explain the presentations and management of movement disorders, including orofacial dyskinesia, oromandibular dystonia, Parkinsonian syndromes, and drug-induced tardive dyskinesias. High-yield: involuntary sustained muscle contractions and abnormal postures, ocular blinking and grimacing in oromandibular dystonia, neuroleptic-associated tardive dyskinesias. Lower: deep brain stimulation and advanced motor-suppressive therapies.

  • Describe the aetiology and clinical features of giant cell arteritis affecting temporomandibular structures, including jaw claudication and systemic signs, and outline diagnostic investigations and corticosteroid management. High-yield: systemic granulomatous vasculitis of medium/large arteries, new-onset headache and scalp tenderness, ESR and temporal artery biopsy, vision-threatening ischaemic complications. Lower: ultrasound and advanced imaging adjuncts.

  • Discuss masticatory muscle pain associated with systemic and central sensitisation disorders, including chronic-pain pathophysiology, fibromyalgia comorbidity, and biopsychosocial management approaches. High-yield: peripheral and central sensitisation mechanisms, imbalance between inhibitory and facilitatory pain pathways, education and behavioural therapies. Lower: detailed pharmacological agents for chronic central pain.

  • Explain the clinical features, diagnosis, and management of headache attributed to temporomandibular disorders, recognising its high comorbidity with myofascial pain. High-yield: headache–myalgia coexistence (7.8-fold increased risk), DC/TMD diagnostic criteria. Lower: lecture thin — supplement with TMD-headache pathophysiology literature.

L34: Neuropathic Orofacial Pain including Burning Mouth Syndrome

  • Outline the aetiology, pathogenesis, clinical features, diagnosis, and management of neuropathic orofacial pain conditions as a class. High-yield: pain mechanisms (nociceptive vs neuropathic vs nociplastic), peripheral and central sensitisation, neuroplasticity. Lower: specific neurophysiological mediators (NMDA, substance P).

  • Distinguish between post-traumatic trigeminal neuropathic pain, persistent idiopathic facial pain, and trigeminal neuralgia based on clinical presentation and diagnostic criteria. High-yield: ICOP diagnostic criteria, differential clinical features, role of imaging and neurological examination. Lower: historical nomenclature alternatives.

  • Explain the classification, pathophysiology, triggers, and pharmacological management of trigeminal neuralgia, including first-line agents and neurosurgical options. High-yield: carbamazepine first-line, HLA-B1502 screening for patients of Asian descent, neurovascular compression mechanism. Lower: specific neurosurgical techniques (microvascular decompression, rhizotomy).*

  • Describe trigeminal post-herpetic neuralgia epidemiology, risk factors, clinical presentation, and management strategies including prevention and topical/systemic therapies. High-yield: prevalence in >50 y post-zoster, early antiviral treatment and vaccination prevention, capsaicin and gabapentinoids. Lower: specific dosing protocols.

  • Outline the differential diagnosis of oral burning and apply a systematic clinical assessment to exclude secondary causes before diagnosing burning mouth syndrome. High-yield: medication-related causes (ACE inhibitors most common), nutritional deficiencies, autoimmune conditions (Sjögren’s), systematic history and blood investigations. Lower: supplement effects (B6, zinc, ArmaForce).

  • Explain the ICOP diagnostic criteria for burning mouth syndrome, including epidemiology, pathophysiology, and evidence-based management. High-yield: diagnosis of exclusion (>2 hours daily for >3 months with normal examination), female predominance, topical/systemic clonazepam, antidepressants, capsaicin mechanism via TRPV1 depletion. Lower: experimental agents (alpha-lipoic acid, palmitoylethanolamide, low-level laser).

  • Discuss the biopsychosocial model in chronic orofacial neuropathic pain, pain-vulnerability predictors, and the role of cognitive behavioural therapy and multidisciplinary management. High-yield: psychological factors (catastrophising, depression, anxiety), Axis II dominance in chronic pain, early specialist referral (within 12 months) improves outcome. Lower: specific psychiatric comorbidities.

L35: Oral Appliance Therapy for Snoring and OSA

  • Explain the role of dentistry in sleep medicine and the scope of practice for dental practitioners managing sleep-disordered breathing and obstructive sleep apnoea. High-yield: dental sleep medicine disciplines, scope limitations, collaboration with sleep physicians. Lower: history of the field, regulatory frameworks.

  • Identify risk factors and validated screening tools for sleep-disordered breathing in the dental setting, including clinical examination findings and questionnaire-based assessment. High-yield: STOP-BANG questionnaire, Epworth Sleepiness Scale, clinical signs (retrognathia, neck circumference, airway crowding), AHI severity classification. Lower: Berlin Questionnaire, OSA-50, consumer wearable device correlations.

  • Describe the pathophysiology of obstructive sleep apnoea and recognise diagnostic testing modalities including polysomnography levels, apnoea–hypopnoea index calculation, and polysomnogram interpretation. High-yield: Level 1 PSG as reference standard, AHI thresholds (mild 5–15, moderate 15–30, severe >30), respiratory events, oxygen desaturation. Lower: Level 2–4 home-testing subtleties, RERA and arousal classification.

  • Explain the mechanism of action, indications, and clinical efficacy of mandibular advancement appliances for managing primary snoring and mild-to-moderate OSA. High-yield: anterior mandibular movement increases velopharyngeal airspace, AHI reduction outcomes, patient preference over CPAP, clinical indications. Lower: tongue-retaining devices, edentulous adaptations.

  • Identify patient characteristics predicting mandibular advancement appliance response versus non-response, including anatomical, clinical, and polysomnographic features. High-yield: responder profile (younger, lower BMI, female, retracted maxilla/mandible); non-responder profile (older, higher BMI, larger neck circumference, nasal obstruction). Lower: loop gain variations, arousal threshold measures.

  • Describe the side effects and craniofacial changes associated with long-term mandibular advancement appliance therapy and explain the clinical rationale for tolerating manageable adverse effects. High-yield: dry mouth (86%), occlusal changes including posterior open bite and decreased overjet, TMJ considerations (typically transient symptoms). Lower: temporary salivation changes, headache incidence, gingival discomfort.

  • Outline the clinical workflow for mandibular advancement appliance therapy, including patient assessment, appliance selection, titration protocol, and criteria for defining treatment success. High-yield: history-taking with Epworth scale, clinical examination of dentition and TMJ, bite registration at 60–70% protrusion, titration in 0.5 mm increments, follow-up PSG with appliance in situ, multidisciplinary coordination with sleep physicians. Lower: appliance design comparisons, George Gauge technique specifics.

L36: Bruxism

  • Describe the evolution, epidemiology, risk factors, aetiology, and pathophysiology of sleep and awake bruxism, distinguishing primary from secondary forms and the protective versus pathological roles of bruxism. High-yield: sleep vs awake bruxism distinction, non-occlusal aetiologies (stress, medications, substance use, OSA), 2018 global consensus redefining bruxism as non-pathological in healthy individuals. Lower: detailed genetic models, historical occlusal-interference theories now obsolete.

  • Describe the clinical features of bruxism through patient history and clinical signs (tooth wear/bruxofacets, masseter hypertrophy, tongue scalloping, linea alba, tooth fractures), and apply the “possible, probable, definite” diagnostic grading. High-yield: case-anchored presentations — dentist with wear/scalloping, SDB patient with OSA–bruxism overlap, female with isolated muscle hypertrophy. Lower: rare signs like tori/exostoses, specificity limitations of individual clinical markers.

  • Explain differential diagnosis and exclusion of movement disorders mimicking bruxism, including tardive dyskinesia, oromandibular dystonia, and secondary causes (seizure, TBI, neurodegenerative disease). High-yield: dementia case with video-confirmed tardive dyskinesia misdiagnosed as bruxism; drug-induced extrapyramidal syndromes. Lower: rare neurodegenerative conditions, forensic classification of dystonia subtypes.

  • Discuss diagnostic investigations and risk-factor assessment including psychological factors (stress, anxiety in college students), substance use (alcohol, cigarettes, cocaine, ADHD/antipsychotic medications), and sleep-disordered breathing screening (OSA-50, STOP-BANG, Epworth, Berlin questionnaire). High-yield: medication-induced bruxism protocols, awake-bruxism stress link from college study, weak OSA–bruxism correlation. Lower: full Berlin questionnaire interpretation, Epworth’s poor sensitivity in women.

  • Explain management principles and decision-making framework: harmless vs risk vs protective behaviour classification, severity assessment (dental damage, musculoskeletal symptoms, TMJ involvement), and indication for treatment. High-yield: severity dictates management; protective bruxism in OSA should not be treated; flat-plane hard-material occlusal splints (not soft) for risk behaviour. Lower: rare splint complications, tooth-movement consent language.

  • Discuss multimodal management strategies including patient education/reassurance, psychosocial therapy and habit reversal, physiotherapy and biofeedback, occlusal splint design and maintenance (flat plane, light contacts, regular checks), and adjuncts (BruxApp). High-yield: splints protect dentition but do not stop muscle activity; soft splints contraindicated; botulinum toxin high-cost, only 4-week efficacy, not indicated for simple bruxism. Lower: detailed BTX-A dosing by muscle, long-term BTX cost-benefit.

  • Describe diagnostic and management considerations for sleep-disordered breathing comorbidity: identifying SDB risk factors (snoring, obesity, age, neck circumference, daytime somnolence), appropriate referral for sleep assessment, the complex and variable relationship between OSA and bruxism, and the recognition that bruxism is sometimes protective for airway patency. High-yield: case-anchored OSA screening (26 y/o male with SDB and splint-wear history; 55 y/o with referral-warranted OSA AHI 84.8), weak bruxism–OSA correlation despite common co-presentation. Lower: detailed AHI/RDI cut-offs, full polysomnographic interpretation.

Graph View